Last reviewed · How we verify

Pseudoephedrine/Paracetamol — Competitive Intelligence Brief

Pseudoephedrine/Paracetamol (Pseudoephedrine/Paracetamol) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Decongestant/analgesic combination. Area: Cold and Flu Symptom Relief.

marketed Decongestant/analgesic combination Alpha-1 adrenergic receptor (pseudoephedrine); COX inhibition (paracetamol) Cold and Flu Symptom Relief Small molecule Live · refreshed every 30 min

Target snapshot

Pseudoephedrine/Paracetamol (Pseudoephedrine/Paracetamol) — McNeil AB. This combination drug reduces nasal congestion via pseudoephedrine's sympathomimetic action and alleviates pain and fever via paracetamol's analgesic and antipyretic effects.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Pseudoephedrine/Paracetamol TARGET Pseudoephedrine/Paracetamol McNeil AB marketed Decongestant/analgesic combination Alpha-1 adrenergic receptor (pseudoephedrine); COX inhibition (paracetamol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Decongestant/analgesic combination class)

  1. McNeil AB · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pseudoephedrine/Paracetamol — Competitive Intelligence Brief. https://druglandscape.com/ci/pseudoephedrine-paracetamol. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: